Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 4/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL796692 | 0.81 | CA2 (0.38) | CA2MAPK1CA1FDPSALDH1A1 | |
| SCHEMBL21556882 | 0.81 | CA2 (0.33) | CA2MAPK1CA1FDPSALDH1A1 | |
| SCHEMBL11496837 | 0.78 | CA2 (0.42) | CA2MAPK1CA1FDPSALDH1A1 | |
| SCHEMBL17607693 | 0.77 | CA2 (0.35) | CA2MAPK1CA1FDPSALDH1A1 | |
| SCHEMBL23512384 | 0.77 | OPRM1 (0.37) | FDPSALDH1A1TDP1TSHRDNM1 | |
| SCHEMBL24066828 | 0.75 | LMNA (0.47) | CA2FDPSALDH1A1TSHRCYP3A4 | |
| SCHEMBL29163123 | 0.73 | FDPS (0.42) | CA2FDPSALDH1A1TSHRDNM1 | |
| SCHEMBL24786125 | 0.71 | — | — | |
| SCHEMBL10242782 | 0.71 | FDPS (0.45) | CA2MAPK1CA1FDPSALDH1A1 | |
| SCHEMBL2349339 | 0.71 | CA2 (0.43) | CA2MAPK1CA1FDPSALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846065-B2 | Ester mixtures and compositions comprising such ester mixtures | COGNIS IP MANAGEMENT GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-20120115949-A1 | Ester Mixtures And Compositions Comprising Such Ester Mixtures | COGNIS IP MANAGEMENT GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
| EP-2448550-A1 | ESTER MIXTURES AND COMPOSITIONS COMPRISING SUCH ESTER MIXTURES | Cognis IP Management GmbH (DE) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011000487-A1 | ESTER MIXTURES AND COMPOSITIONS COMPRISING SUCH ESTER MIXTURES | COGNIS IP MANAGEMENT GMBH (DE) | 2011-01-06 | — | — | WO | disclosed |
| EP-2269566-A1 | Ester mixtures and compositions comprising such ester mixtures | Cognis IP Management GmbH (DE) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115949-A1 | Ester Mixtures And Compositions Comprising Such Ester Mixtures | CES1, CETP, CES2 | CA2 1786/4885MAPK1 4342/4885CA1 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.